Novartis AG
Swiss multinational pharmaceutical corporation developing innovative medicines and generic drugs worldwide.
Financial Snapshot
The Novartis AG Story Through Numbers
Novartis' Destiny 9 energy โ universal, humanitarian and reaching across borders โ is expressed through a medicines portfolio designed to address the largest disease burdens in the world, alongside a commitment to making treatments available in developing markets that bigger-margin strategies would ignore. The CAR-T therapy Kymriah, approved in 2017 as the first gene therapy in the United States, is a 9 breakthrough: a one-time infusion that can cure childhood leukaemia. The "unbossed" culture introduced by CEO Vas Narasimhan โ removing hierarchy to unleash scientific creativity โ is a 9 organisation trying to serve its mission more purely.
Investor alignment: Best aligned with Life Path 9 purpose-driven investors and Life Path 7 biotech-research shareholders who value Novartis' gene therapy and radioligand therapy pipelines.